| Identification | Back Directory | [Name]
Ligufalimab | [CAS]
2428381-55-7 | [Synonyms]
Ligufalimab
Ligufalimab (anti-CD47)
Research Grade Ligufalimab
Research Grade Ligufalimab (DHG17606) |
| Hazard Information | Back Directory | [Uses]
Ligufalimab (AK 117) is a humanized IgG4 anti-CD47 monoclonal antibody. Ligufalimab does not induce RBC hemagglutination, and induces phagocytosis. Ligufalimab shows anti-tumor activity[1]. | [in vivo]
Ligufalimab (0.1, 1 mg/kg for Raji xenograft, 0.2 mg/kg for MDA-MB-231 xenograft model) inhibits tumor growth in mice[1]. | Animal Model: | SCID/Beige mice (Raji xenograft model, MDA-MB-231 xenograft model)[1] | | Dosage: | 0.1, 1 mg/kg for Raji xenograft, 0.2 mg/kg for MDA-MB-231 xenograft model | | Administration: | I.v. | | Result: | Inhibited tumor growth with the tumor inhibition rate of 88.56%, 63.78% at 1, 0.1 mg/kg. |
| [References]
[1] Qu T, et al. Ligufalimab, a novel anti-CD47 antibody with no hemagglutination demonstrates both monotherapy and combo antitumor activity. J Immunother Cancer. 2022 Nov;10(11):e005517. DOI:10.1136/jitc-2022-005517 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|